Immunovant To Stop Development Of IMVT-1402 In Cutaneous Lupus Erythematosus

September 23, 2026 — 07:25 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Immunovant (IMVT) announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 or imeroprubart for the treatment of cutaneous lupus erythematosus. The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12. Immunovant plans to stop development in cutaneous lupus erythematosus.

Immunovant said it remains focused on rapidly advancing the clinical development of IMVT-1402 across multiple autoimmune diseases with significant unmet need, including Graves disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogrens disease.

In pre-market trading on NasdaqGS, Immunovant shares are down 7 percent to $34.68.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Immunovant To Stop Development Of IMVT-1402 In Cutaneous Lupus Erythematosus

Tags

Latest Articles